Michael Sailor
Oprichter bij Impilo Therapeutics, Inc.
Profiel
Michael Sailor is the founder of Impilo Therapeutics, Inc. He currently holds a position as Director at Cend Therapeutics, Inc.
Actieve functies van Michael Sailor
Bedrijven | Functie | Begin |
---|---|---|
Impilo Therapeutics, Inc.
Impilo Therapeutics, Inc. Packaged SoftwareTechnology Services Impilo Therapeutics, Inc. engages in the development of platform for delivering nucleic acid-based medicines to solid tumor cancers. The company was founded by Sangeeta N. Bhatia, Frank J. Slack, and Michael Sailor and is headquartered in San Diego, CA. | Oprichter | - |
Cend Therapeutics, Inc.
Cend Therapeutics, Inc. BiotechnologyHealth Technology Cend Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of therapies for solid tumor cancers. Its offers CendR Platform, which provides a targeted tissue penetration capability to specifically enhance drug delivery to tumors. Its lead compound CEND-1 seeks out tumors and activates the CendR transport pathway. The company was founded by Erkki Ruoslahti in 2016 and is headquartered in San Diego, CA. | Directeur/Bestuurslid | 21-09-2020 |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Bedrijven in privébezit | 2 |
---|---|
Impilo Therapeutics, Inc.
Impilo Therapeutics, Inc. Packaged SoftwareTechnology Services Impilo Therapeutics, Inc. engages in the development of platform for delivering nucleic acid-based medicines to solid tumor cancers. The company was founded by Sangeeta N. Bhatia, Frank J. Slack, and Michael Sailor and is headquartered in San Diego, CA. | Technology Services |
Cend Therapeutics, Inc.
Cend Therapeutics, Inc. BiotechnologyHealth Technology Cend Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of therapies for solid tumor cancers. Its offers CendR Platform, which provides a targeted tissue penetration capability to specifically enhance drug delivery to tumors. Its lead compound CEND-1 seeks out tumors and activates the CendR transport pathway. The company was founded by Erkki Ruoslahti in 2016 and is headquartered in San Diego, CA. | Health Technology |